Noninvasive Intratumor Heterogeneity Evaluation in HNSCC
1 other identifier
observational
700
1 country
1
Brief Summary
This study focuses on tumor heterogeneity, a core challenge in the field of oncology, and innovatively utilizes patient imaging data to deeply mine and analyze intratumoral heterogeneity. By constructing an imaging analysis model for tumor heterogeneity and associating this model with clinical, pathological, transcriptomic, and metabolomic data of patients, a multi-omics decoding of tumor heterogeneity is achieved. The main questions it aims to address are: Can the ITH model stratify patients' treatment efficacy and prognosis assessment? Can pathological and multi-omics sequencing map the mechanisms behind the ITH model?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 27, 2025
CompletedFirst Submitted
Initial submission to the registry
June 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 15, 2025
CompletedFirst Posted
Study publicly available on registry
June 18, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 15, 2025
CompletedJune 18, 2025
June 1, 2025
4 months
June 10, 2025
June 16, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
AUC
through study completion, an average of 1 year
C-index
through study completion, an average of 1 year
Study Arms (3)
Training set
Test set
Pathological set
Eligibility Criteria
Patients with pathologically confirmed HNSCC were collected from the Department of Otolaryngology, the First Affiliated Hospital of Chongqing Medical University.
You may qualify if:
- Pathologically confirmed head and neck squamous cell carcinoma (HNSCC). Complete clinical, imaging, and pathological data. Available complete follow-up information.
You may not qualify if:
- Patients who received chemotherapy or radiotherapy before surgery. Poor image quality. Tumors too small to be easily identified. History of other concurrent malignant tumors.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PHD
Study Record Dates
First Submitted
June 10, 2025
First Posted
June 18, 2025
Study Start
February 27, 2025
Primary Completion
June 15, 2025
Study Completion
August 15, 2025
Last Updated
June 18, 2025
Record last verified: 2025-06